On optimal temozolomide scheduling for slowly growing glioblastomas.
Berta Segura-CollarJuan Jiménez-SanchezRicardo GarginiMiodrag DragojJuan Manuel SepúlvedaMilica PesicMaría A RamírezLuis E Ayala-HernándezVicente A TorresVictor M Pérez-GarcíaPublished in: Neuro-oncology advances (2022)
studies show that TMZ administration schedules with increased time between doses may reduce toxicity, delay the appearance of resistances and lead to survival benefits mediated by changes in the tumor phenotype in slowly-growing GBMs.